Cover Image
市場調查報告書

皮質類固醇移植 (黃斑部水腫·黃斑部病變) :預測·市場分析

Corticosteroid Implants (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325955
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
皮質類固醇移植 (黃斑部水腫·黃斑部病變) :預測·市場分析 Corticosteroid Implants (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
出版日期: 2014年10月31日 內容資訊: 英文 89 Pages
簡介

目前黃斑部水腫·黃斑部病變市場抗VEGF單劑療法的使用佔多數,但近年來皮質類固醇移植的使用也在擴大。皮質類固醇有抑制發炎,抑制特定發炎性細胞激素的釋放,以及抑制VEGF分泌等廣泛的藥理作用。

本報告提供全球皮質類固醇移植 (皮質類固醇移植) 市場相關調查,提供您黃斑部水腫·黃斑部病變概要,治療指南,競爭情形概要,皮質類固醇移植的詳細資訊,並彙整主要6個國家的銷售額預測·銷售額等資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 黃斑部病變概要
    • 病因·病理學
    • 分類
    • 症狀·診斷
  • 黃斑部水腫概要

第4章 疾病管理

  • 診斷·治療概要
    • 黃斑部水腫的診斷
    • 黃斑部病變的診斷
    • 治療指南·主要的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 皮質類固醇移植

  • 概要
    • Ozurdex
    • Retisert
    • Iluvien
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

  • 參考文獻
  • 簡稱
  • 調查手法
  • 預測手法
  • 一次調查:KOL採訪
  • 一次調查:調查亂髮處方籤的醫生調查
  • 關於作者
  • 關於GlobalData
  • 免責聲明

圖表清單

目錄
Product Code: GDHC484DFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Corticosteroids have demonstrated a range of pharmacological actions, including inhibition of inflammation, inhibition of the release of certain inflammatory cytokines, and suppression of VEGF secretion, highlighting this type of biological agent as a potential treatment for various ocular conditions, including DME, dAMD, wAMD, and RVO.Corticosteroids have been used off-label for many years as a treatment for ME and wAMD due to their ability to inhibit inflammation and the release of certain inflammatory cytokines, supress VEGF secretion, and reduce the vascular permeability of the retina.

Scope

  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Corticosteroid Implants including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Corticosteroid Implants for the top six countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Corticosteroid Implants performance.
  • Obtain sales forecast for Corticosteroid Implants from 2013-2023 in top six countries (the US, France, Germany, Italy, Spain and the UK).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Corticosteroid Implants

  • 6.1. Overview
    • 6.1.1. Ozurdex
    • 6.1.2. Retisert
    • 6.1.3. Iluvien
  • 6.2. Efficacy - Diabetic Macular Edema
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed ME and AMD Patients
    • 7.4.2. Percentage of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - High-Prescribers Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
  • Table 5: Leading Treatments for ME and AMD, 2014
  • Table 6: Product Profile - Ozurdex
  • Table 7: Product Profile - Iluvien
  • Table 8: Corticosteroid IVT Implants SWOT Analysis, 2014
  • Table 9: Global Sales Forecast ($m) for Ozurdex, 2013-2023
  • Table 10: Global Sales Forecast ($m) for Iluvien, 2013-2023
  • Table 11: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
  • Figure 11: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME
Back to Top